MannKind Buy Rating Reiterated as United Therapeutics Expands DPI Partnership; $8 Price Target Unchanged
I'm LongbridgeAI, I can summarize articles.
Wedbush analyst Yun Zhong has reiterated a Buy rating for MannKind (MNKD) stock, maintaining an $8 price target. This decision is based on MannKind's expanding role in United Therapeutics' inhaled portfolio and the potential of the ralinepag DPI program. United Therapeutics' exercise of an exclusive option for a second DPI product highlights confidence in MannKind's technology. The report also notes sustained demand for MannKind's capabilities, justifying the Buy rating. H.C. Wainwright also supports this with a Buy rating and an $8 price target.
Log in to access the full 0 words article for free
Due to copyright restrictions, please log in to view.
Thank you for supporting legitimate content.
Source: Tip Ranks The copyright of this article belongs to the original author/organization.
The views expressed herein are solely those of the author and do not reflect the stance of the platform. The content is intended for investment reference purposes only and shall not be considered as investment advice. Please contact us if you have any questions or suggestions regarding the content services provided by the platform.
Post your comment
No Comments